ATP1A3相关疾病的表型连续谱
本研究在Deciphering Developmental Disorders队列及国际合作者中识别出24例携带21种ATP1A3变异的未诊断神经系统表型个体,并系统回顾2004至2021年文献报道的1108例携带168种变异的个体。患者平均经历2-3种发作性事件,永久性神经特征常见,所有患者均有认知障碍,表型高度异质;致病/可能致病变异的CADD评分显著更高且聚集于6个约束区域。作者认为联合发作性事件、多动、神经精神症状和认知障碍及评估CADD评分和变异位置有助于识别ATP1A3相关疾病。
要点
- ATP1A3相关疾病表型高度异质,多数患者不符合已发表的临床诊断标准。
- 所有患者均有认知障碍,常见永久性特征包括共济失调54%、张力障碍42%、小头畸形29%、肌张力低下29%。
- 联合发作性事件、多动、神经精神症状、认知障碍及CADD评分和变异位置有助于识别ATP1A3相关疾病。
核心结论
- ATP1A3相关疾病呈现广泛的表型连续谱,多数个体不符合既往定义的临床表型。
- 联合评估发作性事件、多动、神经精神症状、认知障碍及CADD评分和变异位置,而非单独应用诊断标准,可帮助识别ATP1A3相关疾病。
研究设计与样本
- 在Deciphering Developmental Disorders研究队列中识别携带ATP1A3变异的未诊断个体,并由国际合作者补充病例。
- 通过转诊临床医生填写的问卷收集详细临床数据,并检索PubMed 2004至2021年包含「ATP1A3」的出版物进行文献综述。
主要发现
- 24例具有先前未诊断神经系统表型的个体携带21种ATP1A3变异,其中8种变异既往已发表。
- 患者平均经历2-3种不同类型的发作性事件。
- 永久性神经特征常见:小头畸形7例(29%)、共济失调13例(54%)、张力障碍10例(42%)、肌张力低下7例(29%)。
- 所有患者均有认知障碍,16例(66.6%)报告神经精神诊断,表型高度多样,多数个体不符合既往发表表型的临床标准。
- 文献回顾发现1108例个体携带168种不同ATP1A3变异;致病和可能致病变异的CADD评分显著更高,变异聚集于6个约束区域。
临床怎么用
- 作者认为,寻找发作性事件、多动、神经精神症状和认知障碍的组合,并评估CADD评分和变异位置,可帮助识别ATP1A3相关疾病,而非单独应用诊断标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: ATP1A3 is associated with a broad spectrum of predominantly neurologic disorders, which continues to expand beyond the initially defined phenotypes of alternating hemiplegia of childhood, rapid-onset dystonia parkinsonism, and cerebellar ataxia, areflexia, pes cavus, optic atrophy, sensorineural hearing loss syndrome. This phenotypic variability makes it challenging to assess the pathogenicity of an ATP1A3 variant found in an undiagnosed patient. We describe the phenotypic features of individuals carrying a pathogenic/likely pathogenic ATP1A3 variant and perform a literature review of all ATP1A3 variants published thus far in association with human neurologic disease. Our aim is to demonstrate the heterogeneous clinical spectrum of the gene and look for phenotypic overlap between patients that will streamline the diagnostic process. METHODS: Undiagnosed individuals with ATP1A3 variants were identified within the cohort of the Deciphering Developmental Disorders study with additional cases contributed by collaborators internationally. Detailed clinical data were collected with consent through a questionnaire completed by the referring clinicians. PubMed was searched for publications containing the term "ATP1A3" from 2004 to 2021. RESULTS: Twenty-four individuals with a previously undiagnosed neurologic phenotype were found to carry 21 ATP1A3 variants. Eight variants have been previously published. Patients experienced on average 2-3 different types of paroxysmal events. Permanent neurologic features were common including microcephaly (7; 29%), ataxia (13; 54%), dystonia (10; 42%), and hypotonia (7; 29%). All patients had cognitive impairment. Neuropsychiatric diagnoses were reported in 16 (66.6%) individuals. Phenotypes were extremely varied, and most individuals did not fit clinical criteria for previously published phenotypes. On review of the literature, 1,108 individuals have been reported carrying 168 different ATP1A3 variants. The most common variants are associated with well-defined phenotypes, while more rare variants often result in very rare symptom correlations, such as are seen in our study. Combined Annotation-Dependent Depletion (CADD) scores of pathogenic and likely pathogenic variants were significantly higher and variants clustered within 6 regions of constraint. DISCUSSION: Our study shows that looking for a combination of paroxysmal events, hyperkinesia, neuropsychiatric symptoms, and cognitive impairment and evaluating the CADD score and variant location can help identify an ATP1A3-related condition, rather than applying diagnostic criteria alone.
引用
- Vezyroglou A, Akilapa R, Barwick K, et al. The Phenotypic Continuum of ATP1A3-Related Disorders. Neurology. 2022. PMID: 36192182. doi:10.1212/WNL.0000000000200927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。